Biocryst Pharmaceuticals Inc (NASDAQ: BCRX) flaunted slowness of -3.90% at $6.9, as the Stock market unbolted on Thursday, before settling in for the price of $7.18 at the close. Taking a more long-term approach, BCRX posted a 52-week range of $6.00-$11.31.
It was noted that the giant of the Healthcare sector posted annual sales growth of 14.52% over the last 5 years. Meanwhile, its Annual Earning per share during the time was 14.52%. Nevertheless, stock’s Earnings Per Share (EPS) this year is 128.94%. This publicly-traded company’s shares outstanding now amounts to $210.52 million, simultaneously with a float of $195.88 million. The organization now has a market capitalization sitting at $1.45 billion. At the time of writing, stock’s 50-day Moving Average stood at $7.35, while the 200-day Moving Average is $8.41.
Biocryst Pharmaceuticals Inc (BCRX) Ownership Facts and Figures
Sometimes it is also beneficial to study the sentiment of large-scale investors towards the stock of the Biocryst Pharmaceuticals Inc industry. Biocryst Pharmaceuticals Inc’s current insider ownership accounts for 7.02%, in contrast to 92.50% institutional ownership. Preceding that transaction, on Aug 13 ’25, Company’s Director sold 70,000 for 8.51, making the whole transaction’s value amount to 595,868. This particular insider is now the holder of 65,352 in total.
Biocryst Pharmaceuticals Inc (BCRX) Earnings and Revenue Records
Wall Street market experts anticipate that the next fiscal year will bring earnings of 0.12 per share during the current fiscal year. Biocryst Pharmaceuticals Inc’s EPS increase for this current 12-month fiscal period is 128.94% and is forecasted to reach 0.18 in the upcoming year.
Biocryst Pharmaceuticals Inc (NASDAQ: BCRX) Trading Performance Indicators
Let’s observe the current performance indicators for Biocryst Pharmaceuticals Inc (BCRX). It’s Quick Ratio in the last reported quarter now stands at 1.84. Another valuable indicator worth pondering is a publicly-traded company’s price to sales ratio for trailing twelve months, which is currently 2.42. Similarly, its price to free cash flow for trailing twelve months is now 30.49.
In the same vein, BCRX’s Diluted EPS (Earnings per Share) trailing twelve months is recorded -0.05, a figure that is expected to reach 0.03 in the next quarter, and analysts are predicting that it will be 0.18 at the market close of one year from today.
Technical Analysis of Biocryst Pharmaceuticals Inc (BCRX)
Now, what If we examine the latest scores posted by [Biocryst Pharmaceuticals Inc, BCRX]. During the last 5-days, its volume was better the volume of 4.04 million it reported in year-ago period. During the previous 9 days, stock’s Stochastic %D was recorded 64.16% While, its Average True Range was 41.17.
Raw Stochastic average of Biocryst Pharmaceuticals Inc (BCRX) in the period of the previous 100 days is set at 22.10%, which indicates a major fall in contrast to 40.63% during the last 2-weeks. If we go through the volatility metrics of the stock, In the past 14-days, Company’s historic volatility was 0.27 that was higher than 0.27 volatility it exhibited in the past 100-days period.
